December 26, 2012

MicroProtein Technologies is Now Offering 3 Advanced Recombinant Biologic Products: Protein A, Protein G, and Protein AG

After years of extensive research and product development, MicroProtein Technologies is the first company to produce recombinant biologics on an industrial scale (from MG to KGs) without employing the conventional fermentation process. In an effort to advance the field of biotechnology, MicroProtein is proud to announce its new product offerings: Recombinant Protein A, Recombinant Protein G, and Recombinant Protein AG chimeric, all of which are highly pure, and are available at a low cost compared to less potent proteins currently available on the market.

Protein A

Recombinant Staphylococcal Protein A, produced in our proprietary strain of E. coli, is a non-glycosylated polypeptide chain containing 290 amino acids, and has an approximate molecular mass of 35.1 kDa. The product obtained is consistent in quality and yield because the bacterial platform is engineered to be deficient of major proteolytic activities. Our recombinant Staphylococcal Protein A is purified by proprietary chromatographic techniques to a purity of greater then 95%. Protein A is available for purchase in increments of 20mg, 100mg, and custom sizes upon request.

Protein G

Recombinant Streptococcus Protein G is produced in E. coli and is a non-glycosylated polypeptide chain containing 196 amino acids. Streptococcus Protein G is proprietarily produced in E. coli and purified via chromatographic techniques. The product obtained is consistent in quality and yield because our proprietary bacterial platform is engineered to be deficient of major proteolytic activities. Protein G binds through a non-immune mechanism specifically to the Fc region of IgG and to all the human subclasses. It also has a strong affinity to monoclonal mouse IgG1 and rat IgG. Protein G is available for purchase in increments of 20mg, 50mg, and custom sizes upon request.

Protein AG

The genetic combination of the Fc-binding domains of Protein A and Protein G has lead to the production of a fusion protein that is a structurally and functionally enhanced protein with broader binding than either Protein A or Protein G alone. During fusion, the Protein G gene sequence, coding for the serum albumin-binding site, is eliminated. This fusion protein is proprietarily expressed in our E. coli platform and purified via chromatographic techniques. The product obtained is consistent in quality and yield because the bacterial host is engineered to be deficient of major proteolytic activities. Binding is less pH-dependent than either Protein A or Protein G alone, occurring well at pH 5 to 8. Protein AG is available for purchase in increments of 10mg, 30mg, and custom sizes upon request.

Disclaimer: Each product is furnished for laboratory or bioprocessing purposes and none of the products listed above may be used as a drug for humans or animals.

As an award-winning company, we hope to continue to lead the industry in the production of recombinant biologics for use in biotechnology, diagnostics, biopharmaceuticals, veterinary medicine, and non-clinical academic purposes. With our unique process, we plan to continue paving the way for innovative biotechnology advancements. To learn more about our products, please visit: http://mptbiotechs.com/services/.